Get started
Author

Zhihao Ni

ORCID: 0009-0006-1726-8435
Observed ORCID: 0009-0006-1726-8435
OpenAlex ID: A5004875830
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
2022 · Ming He, Chaoguo Cao, et al. · Signal Transduction and Targeted Therapy · 300
PDF
Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently
2021 · Zimo Yang, Yonghui Sun, et al. · Cell Research · 90
PDF
BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
2023 · Yi Shi, Yuan Liao, et al. · Cell Discovery · 71
PDF
Degradation‐Based Protein Profiling: A Case Study of Celastrol
2024 · Zhihao Ni, Yi Shi, et al. · Advanced Science · 45
PDF
Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics
2019 · Yu Zong, Fang Fang, et al. · Nature Communications · 44
PDF
Developing selective PI3K degraders to modulate both kinase and non-kinase functions
2024 · Zimo Yang, Yan Tong, et al. · Chinese Chemical Letters · 16
IL‑1β promotes osteogenic differentiation of mouse bone marrow mesenchymal stem cells via the BMP/Smad pathway within a certain concentration range
2020 · Hao Wang, Zhihao Ni, et al. · Experimental and Therapeutic Medicine · 16
PDF
Degradation-based protein profiling in target identification and early-stage drug discovery of bioactive natural products
2026 · Zhihao Ni, Yi Shi, et al. · Targetome · 3
PDF
Caspase Recruitment Domain 6 ( CARD6) is the therapeutic target of dihydroartemisinin for lupus nephritis based on Proteolysis Targeting Chimera (PROTAC) technology
2026 · Honglian Li, Zhihao Ni, et al. · British Journal of Pharmacology · 2
Works count: 9
Citation count: 587
H-index: 7
I10-index: 7
Year
Topic
Type